Active Biotech's Prostate Cancer Project TASQ Featured in Molecular Cancer
(Thomson Reuters ONE) -
Lund, Sweden, May 17, 2010 - Molecular Cancer (doi:10.1186/1476-4598-9-107
covering Active Biotech's (NASDAQ OMX Nordic: ACTI) prostate cancer project
TASQ, where pre-clinical studies of TASQ has been performed in order to further
explore its mode of action.
It was concluded that TASQ exhibits anti-tumor activity via inhibition of tumor
angiogenesis. Up-regulation of thrombospondin-1 (TSP1) was identified as one
important component in order to understand and explain the anti-angiogenic
mechanism of TASQ treatment of prostate cancer.
TASQ is presently in development for the treatment of metastatic
castration-resistant prostate cancer. Positive top line data from a phase II
study was reported in December 2009. Complete results from the Phase II trial
will be presented at an upcoming scientific conference during the first half of
2010 and in scientific journals.
Active Biotech AB (publ)
Tomas Leanderson
President & CEO
For further information, please contact
Tomas Leanderson, President & CEO
Tel: +46 46 19 20 95
tomas.leanderson(at)activebiotech.com
Göran Forsberg, VP IR & Business Development
Tel: +46 46 19 11 54
goran.forsberg(at)activebiotech.com
*Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent,
modulates the expression of thrombospondin-1 in human prostate tumors
Anders Olsson, Anders Björk, Johan Vallon-Christersson, John T Isaacs, & Tomas
Leanderson
Notes to editors
About TASQ
The development of TASQ is principally focused on the treatment of prostate
cancer
antiangiogenic compound, meaning that it cuts off the supply of nutrients to the
tumor but it does not belong to the most frequently occurring group of tyrosine
kinase inhibitors. In September 2009, the results from the Phase I trial of TASQ
published in the British Journal of Cancer. The results showed that long-term
continuous oral administration of TASQ seems to be safe and that TASQ might
delay disease progression. It was announced in December 2009 that the primary
endpoint of the Phase II clinical study
higher fraction of patients with no disease progression during the six-month
period of treatment using TASQ, had been reached. The percentage of patients
with disease progression during the six-month period was 43% for patients
treated with TASQ compared with 67% for placebo treated patients. The median
progression-free survival was 24.7 weeks for the TASQ group, compared with 12.9
weeks (p=0.0001) for the placebo group.
About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with
focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase
are laquinimod, an orally administered small molecule with unique
immunomodulatory properties for the treatment of multiple sclerosis, as well as
ANYARA for use in cancer targeted therapy, primarily of renal cancer. Further
key projects in clinical development comprise the three orally administered
compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex(TM) for RA. Please
visit www.activebiotech.com
information.
Active Biotech is required under the Securities Markets Act to make the
information in this press release public. The information was submitted for
publication at 3:30 pm CET on May 17, 2010.
[HUG#1416361]
Active Biotech?s Prostate Cancer Project TASQ Featured in Molecular Cancer: http://hugin.info/1002/R/1416361/366971.pdf
Unternehmensinformation / Kurzprofil:
Datum: 17.05.2010 - 15:31 Uhr
Sprache: Deutsch
News-ID 20993
Anzahl Zeichen: 0
contact information:
Town:
LUND
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 262 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Active Biotech's Prostate Cancer Project TASQ Featured in Molecular Cancer"
steht unter der journalistisch-redaktionellen Verantwortung von
Active Biotech (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
